Although treatment targeting Epidermal Growth Factor Receptor (EGFR) exhibits limited efficacy in treating mCRC harbouring class II BRAF mutations, while a majority of CRC patients with class III BRAF mutation demonstrate responsiveness.24 The gene discussed is EGFR; the disease is colorectal carcinoma.